Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1998 Jun;35(6):450–455. doi: 10.1136/jmg.35.6.450

Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations.

D G Evans 1, L Trueman 1, A Wallace 1, S Collins 1, T Strachan 1
PMCID: PMC1051337  PMID: 9643284

Abstract

Blood samples from 125 unrelated families with classical type 2 neurofibromatosis (NF2) with bilateral vestibular schwannomas have been analysed for mutations in the NF2 gene. A further 17 families fulfilling modified criteria for NF2 have also been analysed. Causative mutations have been identified in 54 (43%) classical families and six (35%) of those fulfilling modified criteria. Forty-two cases from 38 families with truncating mutations had an average age at onset of symptoms of 19 years and diagnosis at 22.4 years. Fifty-one cases from 16 families with splice site mutations (15 from six), missense mutations (18 from six), and large deletions (18 from five) had an average age of onset of 27.8 years and at diagnosis of 33.4 years. Subjects with truncating mutations were significantly more likely to have symptoms before 20 years of age (p<0.001) and to develop at least two symptomatic CNS tumours in addition to vestibular schwannoma before 30 years (p<0.001). There were also significantly fewer multigenerational families with truncating mutations. Four further truncating mutations were in mosaic form and were associated with milder disease than other similar mutations. This large study has confirmed the previous impression that truncating mutations are associated with severe disease, but caution has to be exercised in using mutation type to predict disease course.

Full text

PDF
450

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bijlsma E. K., Wallace A. J., Evans D. G. Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. J Med Genet. 1997 Nov;34(11):934–936. doi: 10.1136/jmg.34.11.934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bourn D., Carter S. A., Evans D. G., Goodship J., Coakham H., Strachan T. A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals. Am J Hum Genet. 1994 Jul;55(1):69–73. [PMC free article] [PubMed] [Google Scholar]
  3. Bourn D., Carter S. A., Mason S., Gareth D., Evans R., Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet. 1994 May;3(5):813–816. doi: 10.1093/hmg/3.5.813. [DOI] [PubMed] [Google Scholar]
  4. Bourn D., Evans G., Mason S., Tekes S., Trueman L., Strachan T. Eleven novel mutations in the NF2 tumour suppressor gene. Hum Genet. 1995 May;95(5):572–574. doi: 10.1007/BF00223872. [DOI] [PubMed] [Google Scholar]
  5. Bourn D., Strachan T. Highly polymorphic dinucleotide repeat at the NF2 gene. Hum Genet. 1995 Jun;95(6):712–712. doi: 10.1007/BF00209494. [DOI] [PubMed] [Google Scholar]
  6. Donner A., Klar N. Methods for comparing event rates in intervention studies when the unit of allocation is a cluster. Am J Epidemiol. 1994 Aug 1;140(3):279–301. doi: 10.1093/oxfordjournals.aje.a117247. [DOI] [PubMed] [Google Scholar]
  7. Evans D. G., Bourn D., Wallace A., Ramsden R. T., Mitchell J. D., Strachan T. Diagnostic issues in a family with late onset type 2 neurofibromatosis. J Med Genet. 1995 Jun;32(6):470–474. doi: 10.1136/jmg.32.6.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Evans D. G., Huson S. M., Donnai D., Neary W., Blair V., Newton V., Harris R. A clinical study of type 2 neurofibromatosis. Q J Med. 1992 Aug;84(304):603–618. [PubMed] [Google Scholar]
  9. Evans D. G., Mason S., Huson S. M., Ponder M., Harding A. E., Strachan T. Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: a clinical and molecular study. J Neurol Neurosurg Psychiatry. 1997 Apr;62(4):361–366. doi: 10.1136/jnnp.62.4.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Evans D. G., Ramsden R., Huson S. M., Harris R., Lye R., King T. T. Type 2 neurofibromatosis: the need for supraregional care? J Laryngol Otol. 1993 May;107(5):401–406. doi: 10.1017/s002221510012328x. [DOI] [PubMed] [Google Scholar]
  11. Jacoby L. B., MacCollin M., Louis D. N., Mohney T., Rubio M. P., Pulaski K., Trofatter J. A., Kley N., Seizinger B., Ramesh V. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet. 1994 Mar;3(3):413–419. doi: 10.1093/hmg/3.3.413. [DOI] [PubMed] [Google Scholar]
  12. Kanter W. R., Eldridge R., Fabricant R., Allen J. C., Koerber T. Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology. 1980 Aug;30(8):851–859. doi: 10.1212/wnl.30.8.851. [DOI] [PubMed] [Google Scholar]
  13. Kluwe L., Bayer S., Baser M. E., Hazim W., Haase W., Fünsterer C., Mautner V. F. Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes. Hum Genet. 1996 Nov;98(5):534–538. doi: 10.1007/s004390050255. [DOI] [PubMed] [Google Scholar]
  14. MacCollin M., Woodfin W., Kronn D., Short M. P. Schwannomatosis: a clinical and pathologic study. Neurology. 1996 Apr;46(4):1072–1079. doi: 10.1212/wnl.46.4.1072. [DOI] [PubMed] [Google Scholar]
  15. Mautner V. F., Lindenau M., Baser M. E., Hazim W., Tatagiba M., Haase W., Samii M., Wais R., Pulst S. M. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996 May;38(5):880–886. doi: 10.1097/00006123-199605000-00004. [DOI] [PubMed] [Google Scholar]
  16. Mérel P., Hoang-Xuan K., Sanson M., Bijlsma E., Rouleau G., Laurent-Puig P., Pulst S., Baser M., Lenoir G., Sterkers J. M. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer. 1995 Feb;12(2):117–127. doi: 10.1002/gcc.2870120206. [DOI] [PubMed] [Google Scholar]
  17. Parry D. M., Eldridge R., Kaiser-Kupfer M. I., Bouzas E. A., Pikus A., Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994 Oct 1;52(4):450–461. doi: 10.1002/ajmg.1320520411. [DOI] [PubMed] [Google Scholar]
  18. Parry D. M., MacCollin M. M., Kaiser-Kupfer M. I., Pulaski K., Nicholson H. S., Bolesta M., Eldridge R., Gusella J. F. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996 Sep;59(3):529–539. [PMC free article] [PubMed] [Google Scholar]
  19. Rouleau G. A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993 Jun 10;363(6429):515–521. doi: 10.1038/363515a0. [DOI] [PubMed] [Google Scholar]
  20. Ruttledge M. H., Andermann A. A., Phelan C. M., Claudio J. O., Han F. Y., Chretien N., Rangaratnam S., MacCollin M., Short P., Parry D. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996 Aug;59(2):331–342. [PMC free article] [PubMed] [Google Scholar]
  21. Sainz J., Figueroa K., Baser M. E., Mautner V. F., Pulst S. M. High frequency of nonsense mutations in the NF2 gene caused by C to T transitions in five CGA codons. Hum Mol Genet. 1995 Jan;4(1):137–139. doi: 10.1093/hmg/4.1.137. [DOI] [PubMed] [Google Scholar]
  22. Su L. K., Johnson K. A., Smith K. J., Hill D. E., Vogelstein B., Kinzler K. W. Association between wild type and mutant APC gene products. Cancer Res. 1993 Jun 15;53(12):2728–2731. [PubMed] [Google Scholar]
  23. Trofatter J. A., MacCollin M. M., Rutter J. L., Murrell J. R., Duyao M. P., Parry D. M., Eldridge R., Kley N., Menon A. G., Pulaski K. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993 Mar 12;72(5):791–800. doi: 10.1016/0092-8674(93)90406-g. [DOI] [PubMed] [Google Scholar]
  24. Watson C. J., Gaunt L., Evans G., Patel K., Harris R., Strachan T. A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Hum Mol Genet. 1993 Jun;2(6):701–704. doi: 10.1093/hmg/2.6.701. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES